IL-18 binding protein protects against contact hypersensitivity

J Immunol. 2003 Aug 1;171(3):1164-71. doi: 10.4049/jimmunol.171.3.1164.

Abstract

Allergic contact dermatitis, the clinical manifestation of contact hypersensitivity, is one of the most common disorders of the skin. It is elicited upon multiple cutaneous re-exposure of sensitized individuals to the sensitizing agent. In this study, we demonstrate that using IL-18 binding protein (IL-18BP) to neutralize IL-18 significantly reduced clinical symptoms in a murine model of contact hypersensitivity. Furthermore, IL-18BP alleviated the relapses during established disease, as indicated by significant protection during re-exposure of mice that had previously undergone a contact hypersensitivity response without treatment. Although edema was not influenced, IL-18BP reduced the number of T cells homing to sites of inflammation, resulting in diminished local production of IFN-gamma. Thus, by preventing the accumulation of effector T cells to the target tissue, IL-18BP appears to be a potent protective mediator to counter skin inflammation during contact hypersensitivity. Taken together with the evidence that IL-18 is present in tissue samples of the human disease, our data reinforces IL-18BP as a candidate for this therapeutic indication.

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Capillary Permeability / immunology
  • Cell Movement / immunology
  • Cells, Cultured
  • Cytokines / antagonists & inhibitors
  • Cytokines / metabolism
  • Dermatitis, Contact / immunology*
  • Dermatitis, Contact / pathology
  • Dermatitis, Contact / physiopathology
  • Dermatitis, Contact / prevention & control*
  • Dinitrofluorobenzene / administration & dosage
  • Down-Regulation / immunology
  • Ear, External / immunology
  • Ear, External / pathology
  • Glycoproteins / administration & dosage
  • Glycoproteins / therapeutic use*
  • Haptens / administration & dosage
  • Humans
  • Inflammation Mediators / administration & dosage
  • Inflammation Mediators / therapeutic use
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-18 / antagonists & inhibitors
  • Interleukin-18 / biosynthesis
  • Interleukin-18 / metabolism*
  • Lymphocyte Count
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Antigen, T-Cell, alpha-beta / immunology
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocyte Subsets / pathology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Cytokines
  • Glycoproteins
  • Haptens
  • Inflammation Mediators
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-18
  • Receptors, Antigen, T-Cell, alpha-beta
  • Tumor Necrosis Factor-alpha
  • interleukin-18 binding protein
  • Dinitrofluorobenzene